News & Updates
Filter by Specialty:

ECHELON-3: Brentuximab vedotin ticks another box on the lymphoma treatment board
01 Jul 2024
byAudrey Abella
A triplet regimen comprising the anti-CD30 antibody-drug conjugate (ADC) brentuximab vedotin (BV) plus lenalidomide and rituximab (R2) inches its way into the R/R DLBCL* treatment path in the prespecified interim analysis of the ECHELON-3 trial, further reinforcing the role of BV in lymphoma treatment.
ECHELON-3: Brentuximab vedotin ticks another box on the lymphoma treatment board
01 Jul 2024
KRYSTAL-12 boosts adagrasib as 2L Tx alternative for KRASG12C-mutated NSCLC
28 Jun 2024
byAudrey Abella
Findings from the phase III KRYSTAL-12 trial underpin the treatment potential of adagrasib for previously treated metastatic non-small cell lung cancer (NSCLC) harbouring a KRASG12C mutation.